JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Simulations Plus Inc

Chiusa

SettoreSettore sanitario

17.15 -2.5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.15

Massimo

18.24

Metriche Chiave

By Trading Economics

Entrata

-70M

-67M

Vendite

-2.1M

20M

P/E

Media del settore

48.528

37.461

Rendimento da dividendi

0.48

Margine di Profitto

-330.585

Dipendenti

243

EBITDA

-79M

-74M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-9.19% downside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.48%

2.33%

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-28M

323M

Apertura precedente

19.65

Chiusura precedente

17.15

Notizie sul Sentiment di mercato

By Acuity

63%

37%

328 / 371 Classifica in Healthcare

Simulations Plus Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 ott 2025, 20:49 UTC

Utili

Correction to Thermo Fisher Article on Oct. 22

23 ott 2025, 23:51 UTC

Discorsi di Mercato

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 ott 2025, 23:37 UTC

Discorsi di Mercato

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 ott 2025, 22:58 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

23 ott 2025, 22:57 UTC

Discorsi di Mercato

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 ott 2025, 22:17 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 ott 2025, 21:41 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 ott 2025, 21:05 UTC

Utili

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 ott 2025, 20:35 UTC

Utili

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 ott 2025, 20:28 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 ott 2025, 20:15 UTC

Discorsi di Mercato
Utili

Global Commodities Roundup: Market Talk

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Adj EPS $1.71

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Sales $5.52B

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q EPS $1.67

23 ott 2025, 20:09 UTC

Utili

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 ott 2025, 20:07 UTC

Utili

Blackstone Looks to IPOs for Investment Exits -- Update

23 ott 2025, 20:05 UTC

Utili

Intel 3Q Gross Margin 38.2% >INTC

23 ott 2025, 20:04 UTC

Utili

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 ott 2025, 20:04 UTC

Utili

Intel: 4Q Guidance Excludes Altera >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Sees 4Q Adj EPS 8c >INTC

Confronto tra pari

Modifica del prezzo

Simulations Plus Inc Previsione

Obiettivo di Prezzo

By TipRanks

-9.19% in calo

Previsioni per 12 mesi

Media 16 USD  -9.19%

Alto 16 USD

Basso 16 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Simulations Plus Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

328 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat